Mucosal (e.g., Nasal, Etc.) Patents (Class 424/434)
-
Patent number: 6391330Abstract: A nasal and pharyngeal spray solution for use in spraying into the nose and mouth to protect the mucosa from noxious viruses, bacteria and fungi and excessive drying, in situations of high risk, such as the cabins of commercial aircraft, is comprised of a saline solution of Proanthocyanidins and ascorbic acid. The ‘fresh mix’ delivery system is an appropriately closed, sterile, oxygen-excluding, pressurized container.Type: GrantFiled: May 11, 2000Date of Patent: May 21, 2002Inventor: Michael A. Ross
-
Patent number: 6391340Abstract: There is described a solid particulate pharmaceutical formulation suitable for application to the nose comprising finely divided additive particles and finely divided drug particles, wherein the mass median diameter of the drug particles is greater than that of the additive particles.Type: GrantFiled: February 24, 2000Date of Patent: May 21, 2002Assignee: AstraZeneca ABInventors: Karin Malmqvist-Granlund, Gordon Santesson, Eva Trofast
-
Publication number: 20020058069Abstract: Use of microparticles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration.Type: ApplicationFiled: November 19, 2001Publication date: May 16, 2002Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCEInventors: Dario Cremaschi, Cristina Porta
-
Patent number: 6387378Abstract: Disclosed herein is a device for storing and/or delivering an effective amount of biological or pharmaceutical material to an animal comprising a tube disposed to contain said biological or pharmaceutical material and sealed at its ends and adapted to provide an opening through which the biological or pharmaceutical material exits and is administered to an intended site of the animal.Type: GrantFiled: September 9, 1993Date of Patent: May 14, 2002Inventors: George P. Shibley, Karen K. Brown, Leszek J. Choromanski, Sharon A. Bryant
-
Patent number: 6387394Abstract: Controlled release powder insufflation formulations are disclosed. The powder formulation includes cohesive composites of particles containing a medicament and a controlled release carrier which preferably includes one or more polysaccharide gums of natural origin.Type: GrantFiled: July 26, 1999Date of Patent: May 14, 2002Assignee: Penwest Pharmaceuticals Co.Inventors: Anand Baichwal, John N. Staniforth
-
Patent number: 6387390Abstract: Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The compositions include a compound to be delivered and a biocompatible viscous material, such as a hydrogel, lipogel, or highly viscous sol. The composition also include, or are administered in conjunction with, an enhancer in an amount effective to maximize expression of or binding to receptors and enhance RME of the compound into the cells. This leads to high transport rates of compounds to be delivered across cell membranes, facilitating more efficient delivery of drugs and diagnostic agents. Compositions are applied topically orally, nasally, vaginally, rectally, and ocularly. The enhancer is administered with the composition or separately, either systemically or preferably locally. The compound to be delivered can also be the enhancer.Type: GrantFiled: October 5, 1999Date of Patent: May 14, 2002Assignee: The Penn State Research FoundationInventors: Daniel R. Deaver, David A. Edwards
-
Patent number: 6383510Abstract: Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.Type: GrantFiled: July 6, 2000Date of Patent: May 7, 2002Assignee: Byk Gulden Lomberg Chemische Fabrik GmbHInventors: Rudolf Linder, Rango Dietrich
-
Patent number: 6375986Abstract: Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.Type: GrantFiled: September 21, 2000Date of Patent: April 23, 2002Assignee: Elan Pharma International Ltd.Inventors: Niels P. Ryde, Stephen B. Ruddy
-
Patent number: 6375975Abstract: Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compounds as described in the specification. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed. A preferred method for administering the present composition is through the buccal region of the mouth.Type: GrantFiled: March 6, 2000Date of Patent: April 23, 2002Assignee: Generex Pharmaceuticals IncorporatedInventor: Pankaj Modi
-
Patent number: 6375974Abstract: A process for obtaining an aqueous fumaric acid solution which is useful in stably obtaining a large amount of aqueous fumaric acid solution. A column is packed with solid fumaric acid and then water is passed through the column, thereby giving an aqueous fumaric acid solution. Water is usually passed in the reverse direction. The solid fumaric acid may be in the form of tablets containing 70% by weight or more of fumaric acid. The aqueous fumaric acid solution thus obtained has a pH value of about 1 to 4. A urinal, etc. is treated with a fumaric acid-containing deodorizing agent to thereby efficiently deodorize nitrogen-containing bad-smelling components over a long period of time. A solid deodorizing agent containing fumaric acid, which has an extremely low solubility and a low dissolution rate in water, is placed on a urinal to deodorize the same.Type: GrantFiled: December 23, 1999Date of Patent: April 23, 2002Assignee: Mitsui Takeda Chemicals, Inc.Inventors: Toshio Ito, Yukio Tanaka
-
Patent number: 6375963Abstract: The present invention includes a hot-melt extruded film and method of preparation thereof. The film is made from a precursor composition containing at least a water soluble or water swellable thermoplastic polymer, preferably HPC and/or PEO, and a bioadhesive polymer. The film can also contain a therapeutic agent, preservative, buffering agent, antioxidant, super-disintegrant or absorbent, flavorant, colorant, water insoluble polymer, organic acid, surfactant, film modifier, and/or cross-linking agent. The film does not contain a conventional plasticizer or a material which is generally recognized in the art as a plasticizer for extruded films. The film can be sized and shaped to provide a controlled delivery of a therapeutic agent to the buccal, rectal, uterine, vaginal, abdominal, cranial, ophthalmic, nasal, sinus, or otic cavities. The film can also be used for the treatment of wounds.Type: GrantFiled: June 15, 2000Date of Patent: April 23, 2002Inventors: Michael A. Repka, Staci L. Repka, James W. McGinity
-
Patent number: 6368616Abstract: An aqueous suspension for nasal administration which contains loteprednol etabonate and microcrystalline cellulose carmellose sodium. This aqueous suspension can be administered to nasal mucosa to treat inflammation or allergy.Type: GrantFiled: July 13, 1999Date of Patent: April 9, 2002Assignee: Senju Pharmaceutical Co., Ltd.Inventor: Koji Doi
-
Patent number: 6368586Abstract: Methods and compositions are provided for enhancing the bioadhesive properties of polymers used in drug delivery devices. The bioadhesive properties of a polymer are enhanced by incorporating a anhydrideoligome into the polymer to enhance the ability of the polymer to adhere to a tissue surface such as a mucosal membrane. Anhydrideoligomes which enhance the bioadhesive properties of a polymer include water-insoluble anhydrideoligomes such as water-insoluble metal oxides, including oxides of calcium, iron, copper and zinc. The anhydrideoligomes can be incorporated within a wide range of polymers including proteins, polysaccharides and synthetic biocompatible polymers. In one embodiment, metal oxides can be incorporated within polymers used to form or coat drug delivery devices, such as microspheres, which contain a drug or diagnostic agent.Type: GrantFiled: March 27, 2000Date of Patent: April 9, 2002Assignee: Brown University Research FoundationInventors: Jules S. Jacob, Edith Mathiowitz
-
Patent number: 6365624Abstract: A viscous gel for delivering minor effective homeopathic amount of zinc or another metal to the nasal membrane.Type: GrantFiled: June 26, 2000Date of Patent: April 2, 2002Assignee: Gel Tech, L.L.C.Inventors: Robert S. Davidson, Charles Hensley, Gary S. Kehoe
-
Patent number: 6365146Abstract: Polymers are provided having a structure selected from: R(—O—R1,)x and R(—NH—R1)x wherein R(—O—)x is a polyol moiety and R(—NH—)x is a polyamine moiety, with the x being between 2 and 10, inclusive, and each R1 independently has the structure: wherein a divalent amino acid moiety with R2 being a covalent bond or having from 1 to 8 carbon atoms, and y and z are between 0 and 10, inclusive, provided that y and z are not both 0; is a divalent dicarboxylic acid moiety in which R3 is an alkylene or cyclolkylene group containing from 1 to about 15 carbon atoms substituted with a total of from 1 to about 10 hydroxyl groups, with at least a portion of the hydroxyl groups being acylated with 3 to 24 carbon atom carboxylic acids; and R4 is a poly(alkylene oxide) having the structure: R5—(R6—O—)a—R6—Q— with R5 selected from 1 to 40 carbon atom alkyl groups, —OH—, &mdaType: GrantFiled: April 23, 1999Date of Patent: April 2, 2002Assignee: Rutgers, The State University of New JerseyInventor: Kathryn E. Uhrich
-
Patent number: 6358060Abstract: A two-stage medicine delivery system provides an initial dose of medicine and a second dose of medicine. The initial second doses are capable of achieving a rapid pharmacological effect and a prolonged pharmacological effect, respectively. The two-stage medicine delivery system preferably delivers a craving reduction substance, in which case, the rapid and prolonged pharmacological effects include a rapid and prolonged craving reduction. Preferably, the delivery system is a nicotine delivery system which is provided in chewing gum form or lozenge form and which provides the nicotine in a transmucosally absorbable form. The two-stage medicine delivery system preferably releases a buffering agent which increases a pH level in a user's mouth to facilitate absorption of the medicine when the delivery system is placed in the user's mouth. A method of making the medicine delivery system also is provided. The system and apparatus can be adapted to reduce cravings for alcohol, food, drugs (e.g.Type: GrantFiled: September 3, 1998Date of Patent: March 19, 2002Assignee: JSR LLCInventors: John M. Pinney, Jack E. Henningfield, Saul Shiffman, Joseph Gitchell, Edward J. Cone
-
Patent number: 6358518Abstract: A creamy composition in the form of an oil-in-water emulsion comprising an oily phase dispersed in an aqueous phase, characterized in that it contains at least one anionic emulsifier which is liquid at room temperature, and at least 5% by weight of one or more waxes relative to the total weight of the composition, and in that the oily phase is in the form of a soft paste at room temperature. The anionic emulsifier is preferably a surfactant containing a phosphate group, such as octyldecyl phosphate. The present invention also relates to the uses of the said composition in cosmetics and dermatology, in particular for caring for, treating and/or making up the skin and/or mucous membranes, and more particularly for treating wrinkles and/or fine lines of the skin and/or for treating dry skin. The invention also relates to a process for preparing this composition, characterized in that at least one step of the process is carried out using a mixer-extruder.Type: GrantFiled: January 19, 2001Date of Patent: March 19, 2002Assignee: L'OrealInventors: Veronique Roulier, Pascal Simon
-
Publication number: 20020031539Abstract: The present invention is directed to certain oxidized forms of retinoic acid and their precursors that have been found to be effective in treating conditions that respond to agents that bind to and activate the human peroxisome proliferator activated receptor-gamma. Specific compounds include oxidized all-trans retinoic acid; oxidized 9-cis retinoic acid; and reduced 4-oxo-retinoic acid. The compounds may be used in treating a number of diseases or conditions including diabetes, low body weight, atherosclerosis, and certain forms of cancer.Type: ApplicationFiled: August 29, 2001Publication date: March 14, 2002Applicant: The Brigham and Women's Hospital, Inc.Inventors: Jorge Plutzky, Ouliana Ziouzenkova
-
Patent number: 6355226Abstract: A method of treating patients having viral infections including herpes simplex virus 1 and 2 infections and human papillomavirus infections by topically administering Product R, a peptide-nucleic acid preparation, by itself or in a composition comprising Product R and other pharmaceutically acceptable carriers for topical administration, is disclosed.Type: GrantFiled: August 30, 2000Date of Patent: March 12, 2002Assignee: Advanced Viral Research Corp.Inventor: Shalom Z. Hirschman
-
Publication number: 20020028843Abstract: The invention provides stable pharmaceutical preparations for topical and nasal uses, comprising Mupirocin calcium amorphous as an anti-microbial active agent therein, dissolved in a pharmaceutically acceptable solvent providing stability therefore.Type: ApplicationFiled: July 18, 2001Publication date: March 7, 2002Inventors: Ilana Lavon, Amira Zeevi, Stephen Cherkez, Moshe Arkin, Joseph Kaspi, Chalil Abu-Gnim, Yoav Racchav
-
Patent number: 6352711Abstract: Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions.Type: GrantFiled: November 30, 1999Date of Patent: March 5, 2002Inventor: Phillip Campbell
-
Publication number: 20020026005Abstract: A bioadhesive composition for use as a skin adhesive, the composition formed by polymerising with cross-linking and/or entanglement an aqueous reaction mixture comprising effective amounts of at least one monomer dissolved or suspended therein and capable of forming a hydrogel on polymerisation, optionally at least one cross-linking agent for the monomer, and water, said composition having an elastic modulus (G′) and a viscous modulus (G″), wherein the degree of polymerisation and/or the degree of cross-linking and/or entanglement are selected to control the skin adhesion properties of the bioadhesive composition having regard to the rate of change of tan delta (G″÷G″) against frequency in a diagnostic portion of the frequency range 0.01 to 300 rad/s, typically the lower end of the said frequency range below about 100 rad/s.Type: ApplicationFiled: July 27, 2001Publication date: February 28, 2002Inventor: Hugh Semple Munro
-
Patent number: 6350467Abstract: A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.Type: GrantFiled: June 28, 1999Date of Patent: February 26, 2002Assignee: Antioxidant Pharmaceuticals Corp.Inventors: Harry B. Demopoulos, Myron L. Seligman
-
Patent number: 6350465Abstract: A method of treating headaches by blocking the sphenopalatine ganglion comprises using a first device to anesthetize a front portion of the nasal cavity. A second device is used to anesthetize a rear portion of the nasal cavity. After these priming anesthetizations, a primary pain medication delivery device is used to discharge an anesthetic to the sphenopalatine ganglion to treat the headache.Type: GrantFiled: January 17, 2001Date of Patent: February 26, 2002Inventors: Murali M. R. Jonnalagadda, Venkata Thirumala Devi-Jonnalagadda
-
Patent number: 6350458Abstract: Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in micellar form are disclosed. The micelles are formed from an alkali metal alkyl sulfate, and at least one additional micelle-forming compound as described in the specification. An alkali metal salicylate and a pharmaceutically acceptable edetate are also included in the composition. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed.Type: GrantFiled: April 6, 2000Date of Patent: February 26, 2002Assignee: Generex Pharmaceuticals IncorporatedInventor: Pankaj Modi
-
Patent number: 6348208Abstract: Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Desmethylselegiline is the R-(−) enantiomer of N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane. Claimed compositions include both the R-(−) isomer and mixtures of the R-(−) and S(+) isomers. Pharmaceutically acceptable acid addition salts may also be used. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.Type: GrantFiled: July 12, 1996Date of Patent: February 19, 2002Assignee: Somerset Pharmaceuticals, Inc.Inventors: Cheryl D. Blume, Anthony R. DiSanto
-
Patent number: 6348508Abstract: The present invention is directed to a method of treating dry eye by instilling eyedrops of a composition containing a cationic cellulosic polymer. Such compositions have been found to alleviate the symptoms of dry eye without requiring the presence of anionic therapeutic agents. Low ionic strength solutions are particularly preferred.Type: GrantFiled: April 4, 2000Date of Patent: February 19, 2002Assignee: Bausch & Lomb IncorporatedInventors: John Denick, Jr., David J. Heiler, Zhenze Hu, Joseph C. Salamone, Richard V. Smerbeck
-
Publication number: 20020018800Abstract: A two-stage medicine delivery system provides an initial dose of medicine and a second dose of medicine. The initial and second doses are capable of achieving a rapid pharmacological effect and a prolonged pharmacological effect, respectively. The two-stage medicine delivery system preferably delivers a craving reduction substance, in which case, the rapid and prolonged pharmacological effects include a rapid and prolonged craving reduction. Preferably, the delivery system is a nicotine delivery system which is provided in chewing gum form or lozenge form and which provides the nicotine in a transmucosally absorbable form. The two-stage medicine delivery system preferably releases a buffering agent which increases a pH level in a user's mouth to facilitate absorption of the medicine when the delivery system is placed in the user's mouth. A method of making the medicine delivery system also is provided. The system and apparatus can be adapted to reduce cravings for alcohol, food, drugs (e.g.Type: ApplicationFiled: September 3, 1998Publication date: February 14, 2002Inventors: JOHN M. PINNEY, JACK E. HENNINGFIELD, SAUL SHIFFMAN, JOSEPH GITCHELL, EDWARD J. CONE
-
Patent number: 6344210Abstract: A composition is disclosed for freshening sinus cavities, including a carrier of the ingredients and a masking agent for concealing or eliminating odors that emanate from the sinus cavities. The disclosure is also related to a composition for cleansing and freshening nostrils and sinus cavities that includes a saline solution as a moisturizing base component, a flavoring agent, a preservative, an antiseptic and/or anti-microbial agent, a counter-irritant, and an alcohol. The disclosure is also related to the use of such composition to provide many unexpected benefits of clean and healthy nasal and sinus passages.Type: GrantFiled: February 16, 2001Date of Patent: February 5, 2002Inventor: Charles A. Fust
-
Patent number: 6344204Abstract: A cosmetic and/or dermatological composition in the form of a water-in-oil emulsion comprising (1) at least one silicone emulsifier, (2) at least one branched-chain hydrocarbonaceous oil and (3) at least one volatile silicone oil, the total amount of branched-chain hydrocarbonaceous oil and of volatile silicone oil representing at least 50% by weight of the oily phase. This composition may be used, for example, for caring for, making up, cleansing and/or removing make-up from the skin, mucous membranes, eyes and/or hair.Type: GrantFiled: January 24, 2000Date of Patent: February 5, 2002Assignee: L'OrealInventor: Raluca Lorant
-
Publication number: 20020012688Abstract: The present invention relates to a powdery composition for nasal administration, which is characterized in thatType: ApplicationFiled: August 26, 1998Publication date: January 31, 2002Inventors: MASAHIKO DOHI, YOSHIHISA NISHIBE, YUJI MAKINO, TAKAO FUJII
-
Patent number: 6342246Abstract: The use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, testosterone and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male erectile dysfunction.Type: GrantFiled: July 12, 1999Date of Patent: January 29, 2002Assignee: R.P. Scherer LimitedInventors: Edward Stewart Johnson, Anthony Clarke, Richard David Green
-
Publication number: 20020009478Abstract: The present invention relates to a per oral, oral, or intranasal pharmaceutical mucoretentive, aqueous liquid composition comprising from about 2% to about 50%, by weight of the composition, of colloidal particles of silica, titanium dioxide, clay, and mixtures thereof and a safe and effective amount of a pharmaceutical active selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antihistamines, sensory agents, gastrointestinal agents, and mixtures thereof; wherein the composition has a sedimentation volume ratio of greater than about 0.90 and wherein the triggered viscosity ratio of the composition is at least about 1.2. The present invention further relates to a method of coating the alimentary canal and nasal mucosa, in particular to a method of preventing or treating symptoms of upper respiratory tract infections or upper respiratory tract tissue irritation or damage, by administering a safe and effective amount of the above composition.Type: ApplicationFiled: July 27, 1999Publication date: January 24, 2002Inventor: DOUGLAS JOSEPH DOBROZSI
-
Patent number: 6333045Abstract: There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (±)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.Type: GrantFiled: April 21, 2000Date of Patent: December 25, 2001Assignees: Senju Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd.Inventors: Shinichi Yasueda, Katsuhiro Inada
-
Patent number: 6333044Abstract: An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.Type: GrantFiled: February 1, 1995Date of Patent: December 25, 2001Assignee: Recordati, S.A. Chemical and Pharmaceutical CompanyInventors: Giancarlo Santus, Giuseppe Bottoni, Ettore Bilato
-
Patent number: 6333046Abstract: To provide a transmucous absorption enhancer comprising a medium-chain fatty acid salts or a bile acid salt and a glycyrrhizic acid salts capable of sustaining the effect of the absorption enhancer and allowing an agent (especially a physiologically active peptide) to be absorbed via a mucosa (especially a large intestine mucosa).Type: GrantFiled: November 27, 2000Date of Patent: December 25, 2001Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Michinori Sakai, Hiroshi Ohtake, Hidekazu Azuma, Masaki Otagiri, Teruko Imai
-
Publication number: 20010053379Abstract: This invention pertains to a method that can control, treat, and prevent Diabetes Mellitus. The method includes means of administering a potent product, including mainly the active ingredient Linalool, in any one of several forms, alone or with other additives and catalysts, such as vitamin E to enable the body to handle and control, then correct the complications of Diabetes Mellitus. A modest percentage of users suffering from this disease can be cured completely while the majority of others improve remarkably and experience lower blood glucose and reduce the glycated hemoglobin HbAlc readings to what are medically acceptable and healthy levels. Others, who are vulnerable to the disease due to hereditary factors, or other reasons, can help prevent it. The method works in several ways, including activation of the pancreas and re-establishing the ability of body cells to utilize and handle better and well, the glucose in the blood, and regulate the level of natural insulin in the body.Type: ApplicationFiled: January 2, 2001Publication date: December 20, 2001Applicant: DIABEX INC.Inventors: Osama Mansour Murad, Husni Abu Seir, Hafez Taji Farouqi
-
Patent number: 6328967Abstract: A microsphere containing an immunogen bound to an inert particle having a mesh size of greater than about 35 mesh for site-specific release and induction of an immune response. The immune response may be an overall enhanced T lymphocyte immune response or a selective response. The physical and chemical characterigticg and/or modes of administration of the microsphere may be engineered to increase TH1 lymphocytes for treatment of cancer or infectious disease. The microencapsulated immunogen has an enteric coating for oral administration.Type: GrantFiled: March 12, 1998Date of Patent: December 11, 2001Assignee: Allergenics, Inc.Inventor: Roberto L. Rivera
-
Patent number: 6325993Abstract: An oral adhesive preparation has a substrate and a pressure-sensitive adhesive layer provided on at least one surface of the substrate, in which the pressure-sensitive adhesive layer contains a medicine, and is substantially insoluble in water or absorbs substantially no water. Further, an oral adhesive sheet comprising a separator release-treated on one or both surfaces thereof and a plurality of sections for application to oral mucous membrane mounted on at least one surface of the separator in a specified 2 to 5 by 2 to 5 arrangement with a specified proportion of a minimum inner diameter, Dp, of an incircle passing a center of gravity, W, of a section to a shortest distance, Di, of an adjacent section is 1.5 to 6. The substrate is preferably cloth such as non-woven fabric. Sections containing a local anesthetic can be used in surface anesthesia in dentistry.Type: GrantFiled: February 29, 2000Date of Patent: December 4, 2001Assignee: Nitto Denko CorporationInventors: Junichi Saito, Yuichi Inoue
-
Publication number: 20010046973Abstract: Contact lens care compositions for the treatment of hard contact lenses are disclosed. The compositions are useful for rinsing, cleaning, disinfecting and storing of hard contact lenses. The compositions contain an unique gelling system involving galactomannan polysaccharides and borates to allow for the conditioning of the lens when it is reinserted in the eye of the user. Methods of using these compositions are also disclosed.Type: ApplicationFiled: June 18, 2001Publication date: November 29, 2001Inventor: Bahram Asgharian
-
Patent number: 6322804Abstract: An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.Type: GrantFiled: May 2, 2000Date of Patent: November 27, 2001Assignee: Neurotech S.A.Inventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasconcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 6319513Abstract: The present invention relates to a per oral, oral, or intranasal pharmaceutical mucoretentive, aqueous liquid composition comprising from about 2% to about 50%, by weight of the composition, of colloidal particles of silica, titanium dioxide, clay, and mixtures thereof and a safe and effective amount of a pharmaceutical active selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antihistamines, sensory agents, gastrointestinal agents, and mixtures thereof; wherein the composition has a sedimentation volume ratio of greater than about 0.90 and wherein the triggered viscosity ratio of the composition is at least about 1.2. The present invention further relates to a method of coating the alimentary canal or nasal mucosa, in particular to a method of preventing or treating symptoms of upper respiratory tract infections or upper respiratory tract tissue irritation or damage, by administering a safe and effective amount of the above composition.Type: GrantFiled: July 27, 1999Date of Patent: November 20, 2001Assignee: The Procter & Gamble CompanyInventor: Douglas Joseph Dobrozsi
-
Patent number: 6312711Abstract: The invention concerns a pharmaceutical and/or food composition comprising a suitable pharmaceutical and/or food vehicle and a heat shock protein and at least conformation or sequential epitopes of an antigenic structure inducing a graft versus host, an allergic or autoimmune reaction.Type: GrantFiled: October 28, 1999Date of Patent: November 6, 2001Assignee: Universite Libre de BruxellesInventors: Jean Duchateau, Genevieve Servais
-
Patent number: 6309671Abstract: A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 10° C. (i.e. Tg−Ts is greater than 10° C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage form having a moisture barrier, in combination with appropriate labelling instructions.Type: GrantFiled: October 14, 1997Date of Patent: October 30, 2001Assignee: Inhale Therapeutic SystemsInventors: Linda C. Foster, Mei-chang Kuo, Shelia R. Billingsley
-
Patent number: 6306845Abstract: The present invention provides a method for treating a demyelinating disease in a subject which includes administering to the subject a therapeutically effective amount of a high affinity neuromodulatory Na,K-ATPase so as to treat the demyelinating disease.Type: GrantFiled: January 29, 1999Date of Patent: October 23, 2001Assignee: The Trustees of Columbia University in the City of New YorkInventor: Vincent P. Butler, Jr.
-
Patent number: 6303147Abstract: The present invention is concerned with bioadhesive pharmaceutical compositions comprising a pharmaceutically effective amount of an active ingredient, from 80% to 98.8% (w/w/) pre-gelatinized starch, and from 1% to 10% (w/w) of a hydrophilic matrix forming polymer, characterized in that the composition further comprises from 0.2% to 5% (w/w) alkaliC16-22alkyl fumarate as a lubricant; solid dosage forms such as tablets which are suitable for oral, nasal, rectal and vaginal administration; processes of preparing the compositions and solid dosage forms.Type: GrantFiled: June 19, 1998Date of Patent: October 16, 2001Assignee: Janssen Pharmaceutica, N.V.Inventor: Paul Marie Victor Gilis
-
Patent number: 6299861Abstract: On account of the surprisingly powerful and long-lasting effect thereof, the salts of the L-(−)-enantiomer of (endo, syn)-(−)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(methylethyl)-8-azoniabicyclo [3,2,1]octane are suitable as active substances for drugs administered by inhalation for respiratory tract therapy.Type: GrantFiled: August 6, 1999Date of Patent: October 9, 2001Assignee: Boehringer Ingelheim KGInventors: Rolf Banholzer, Richard Reichl, Bernd Disse, Georg Speck
-
Patent number: 6294188Abstract: The first aspect of the invention relates to a method of inducing changes in the cervical mucus of a person to achieve a contraceptive effect, and wherein the method involves administering to the person an effective amount of ebrotidine sufficient to achieve a contraceptive effect. The second aspect of the invention involves a method for treating atrophic vaginitis urinary incontinence and their associated signs and symptoms, in a person, the method involves administering to the person an effective mount of an agent sufficient to treatment of atrophic vaginitis, the agent being selected from a group consisting of stimulants or antagonists, purinergic receptors, a sodium ion update agents and an anion secretion inhibitors.Type: GrantFiled: July 2, 1999Date of Patent: September 25, 2001Assignee: Aviana BioPharm Inc.Inventors: Vanaja V. Ragavan, Alan Laties
-
Patent number: 6290987Abstract: A mixed liposome pharmaceutical formulation with multilamellar vesicles is provided. The formulation comprises a pharmaceutical agent, water, an alkali metal alkyl sulfate, at least one membrane mimetic amphiphile, and at least one phospholipid. When aerosol delivery is intended, the formulation also comprises a propellant and a phenol. A metered dose dispenser containing the formulation, as well as a method of administering the formulation, are also provided.Type: GrantFiled: September 7, 1999Date of Patent: September 18, 2001Assignee: Generex Pharmaceuticals, Inc.Inventor: Pankaj Modi
-
Patent number: 6290984Abstract: The present invention relates to a non water-soluble pharmaceutical carrier gel which adheres to mucosal surfaces and body tissues upon application and forms a film, providing protection and delivery of pharmaceutical to the site of application, surrounding body tissues, and bodily fluids. The gel comprises a volatile or diffusing nonaqueous solvent and at least one non-water-soluble alkyl cellulose or hydroxyalkyl cellulose. A bioadhesive polymer may also be added. The gel provides an effective residence time with ease of use.Type: GrantFiled: July 30, 1999Date of Patent: September 18, 2001Assignee: Virotex CorporationInventors: Gilles H. Tapolsky, David W. Osborne